ChromaDEX SCIENTIFIC COMMUNICATIONS + B2B CONTENT
“COMMUNICATIONS ENGINE,” HCP-FOCUSED CONTENT, AND ONGOING THOUGHT LEADERSHIP
ChromaDex was heavily engaged with the scientific community and regularly disseminated emerging clinical and preclinical studies that used its proprietary NAD+ booster to investigate the role of NAD+ and cellular metabolism across a range of health outcomes and conditions, including Parkinson’s disease, Alzheimer’s, chronic kidney disease (CKD), rare orphan diseases, and more. We created a pipeline for sharing the latest science with the appropriate audiences.
We also created whitepapers and other aids for HCPs that outlined the benefits of increasing NAD+ for specific health outcomes.
Thought leadership was an important aspect of being “the NAD+ company”; I was part of the team that wrote an op-ed for our CEO about the challenges of the current dietary supplement industry.
Natural Products Insider op-ed cowritten with ChromaDex CEO Rob Fried, head of PR, SVP of scientific affairs, and head of legal:
Scientific communications email series disseminating new study findings:
Inflammation whitepaper for HCPs:
“State of the Science” download on Niagen NR (Oct 2024 update):
